Gilead Sciences press release
Gilead Sciences, Inc. announced results from the PURPOSE 5 trial showing significantly higher persistence — defined as consistent and continuous on-time use—among people starting twice-yearly injectable lenacapavir for HIV prevention as PrEP, compared with those starting daily oral emtricitabine/tenofovir disoproxil fumarate (F/TDF). The trial included people in the United Kingdom and France who would benefit from PrEP.
Key highlights:
- Twice-yearly lenacapavir achieved significantly higher one-year PrEP persistence than daily oral F/TDF, with 85.6% of participants receiving twice-yearly lenacapavir remaining persistent through Week 52 compared with 46.3% for participants taking once-daily F/TDF (p<0.0001).
- PURPOSE 5 is the first randomized study specifically designed to compare persistence between a long-acting HIV prevention option and daily oral PrEP among individuals not currently taking PrEP.
- Zero HIV acquisitions occurred among participants receiving twice-yearly lenacapavir during the 52-week study period.
- Results highlight the potential of twice-yearly lenacapavir to address persistence challenges that can limit the effectiveness of HIV prevention efforts.
Read the full press release here.
Source : Gilead Sciences
Related HIV and Co-Infections News
-
TheBodyPro | To re-engage patients on PrEP, we need to focus on why they stopped
-
NIH | Integrated health service delivery through medical mobile units helped to reduce deaths among individuals at risk for HIV who also inject drugs
-
[Joint press release] Unitaid | US FDA approves first generic injectable lenacapavir for HIV prevention
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.